Morgan Stanley highlighted in a research report that China's State Administration for Market Regulation (SAMR) has conditionally approved Synopsys' (SNPS.US) $35 billion acquisition of Ansys (ANSS.US). The investment bank interprets this development as eliminating the final major regulatory barrier, forecasting the merger will substantially reinforce Synopsys' leadership in the Electronic Design Automation (EDA) market long-term.

Approval carries multiple stipulations: Synopsys must divest its optical and photonics simulation operations, while Ansys must spin off power analysis software assets. Both entities must honor existing Chinese client contracts—maintaining pricing, service levels, and prohibiting product bundling. Additionally, their EDA tools must support industry-standard formats, sustain interoperability agreements with Chinese customers, and establish new interoperability pacts with third-party EDA providers upon client request. Crucially, neither firm may terminate or decline renewals of existing Chinese contracts without valid justification.

Morgan Stanley observes these terms align closely with conditions set by U.S. and European regulators, noting interoperability remains standard industry practice. The non-renewal prohibition, however, appears tailored to ensure Chinese clients' continued tool access—potentially addressing concerns stemming from the U.S. Commerce Department's Bureau of Industry and Security (BIS) earlier proposal (since rescinded) to restrict EDA exports to China.

This transaction endured prolonged scrutiny amid U.S.-China trade tensions and potential chip-design software export controls. SAMR's clearance delivers a significant positive catalyst for Synopsys. Morgan Stanley emphasizes this marked the last major obstacle, anticipating imminent deal closure. Synopsys may update investors during its earnings call around August 20.

Long-term, the merger is projected to cement Synopsys' EDA market supremacy. Morgan Stanley maintains that explicit approval signals should catalyze stock rerating, reiterating an Overweight rating with a $540 price target.